Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in diseases of the skeleton.
Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in diseases of the skeleton.
复制标题
DOI：
10.1002/jcb.22701
复制
发表时间：
2010-10-01
影响因子：
4
通讯作者：
Ponnazhagan, Selvarangan
中科院分区：
文献类型：
--
作者：
Chanda, Diptiman;Kumar, Sanjay;Ponnazhagan, Selvarangan
间充质干细胞（MSC）是组织工程和再生医学中最受欢迎的成体干细胞。自从 60 年代末和 70 年代初发现和功能表征以来，MSC 或 MSC 样细胞已从各种中胚层和非中胚层组织中获得，尽管大多数治疗应用涉及骨髓来源的 MSC。基于其间充质起源，早期预测间充质干细胞只能分化为骨、软骨、脂肪或肌肉等间生谱系。然而，不同的分离和细胞培养方法鉴定了骨髓中的间充质干细胞亚群，它们不仅分化为间充质谱系，而且还分化为外胚层和内胚层衍生物。尽管真正的多能状态尚未确定，但间充质干细胞已分别成功用于骨质疏松性骨折和关节炎的骨和软骨再生以及心肌梗塞后的心脏组织修复。间充质干细胞的免疫抑制特性扩展了间充质干细胞的用途，以减少移植物抗宿主病和类风湿性关节炎的并发症。间充质干细胞归巢至组织损伤部位（包括肿瘤）的情况已得到充分证实。除了组织再生能力外，间充质干细胞还可以进行离体基因工程，作为细胞治疗载体将治疗分子递送到损伤或肿瘤发生部位。间充质干细胞往往会失去运输的表面受体，据报道在长期培养中会形成肉瘤。在本文中，我们回顾了间充质干细胞的现状，特别强调其在骨相关疾病中的治疗应用。
Mesenchymal stem cells (MSCs) are the most popular among the adult stem cells in tissue engineering and regenerative medicine. Since their discovery and functional characterization in the late sixties and early seventies, MSCs or MSC-like cells have been obtained from various mesodermal and non-mesodermal tissues, although majority of the therapeutic applications involved bone marrow derived MSCs. Based on its mesenchymal origin, it was predicted earlier that MSCs only can differentiate into mesengenic lineages like bone, cartilage, fat or muscle. However, varied isolation and cell culturing methods identified subsets of MSCs in the bone marrow which not only differentiated into mesenchymal lineages, but also into ectodermal and endodermal derivatives. Although, true pluripotent status is yet to be established, MSCs have been successfully used in bone and cartilage regeneration in osteoporotic fracture and arthritis respectively and in the repair of cardiac tissue following myocardial infarction. Immunosuppressive properties of MSCs extend utility of MSCs to reduce complications of graft versus host disease and rheumatoid arthritis. Homing of MSCs to sites of tissue injury, including tumor, is well established. In addition to their ability in tissue regeneration, MSCs can be genetically engineered ex vivo for delivery of therapeutic molecule(s) to the sites of injury or tumorigenesis as cell therapy vehicles. MSCs tend to lose surface receptors for trafficking and have been reported to develop sarcoma in long-term culture. In this article, we reviewed the current status of MSCs with special emphasis to therapeutic application in bone-related diseases.
登录
查看更多内容
影响因子：
2.8
作者：
Brown P;Hunger SP;Smith FO;Carroll WL;Reaman GH
通讯作者：
Reaman GH
血管内皮生长因子可以通过血小板衍生的生长因子受体发出信号。
影响因子：
7.8
作者：
Ball, Stephen G;Shuttleworth, C Adrian;Kielty, Cay M
通讯作者：
Kielty, Cay M
影响因子：
4.9
作者：
Chen FH;Tuan RS
通讯作者：
Tuan RS
影响因子：
10.1
作者：
De Becker, Ann;Van Hummelen, Paul;Van Riet, Ivan
通讯作者：
Van Riet, Ivan
影响因子：
4.7
作者：
Centeno, Christopher J.;Busse, Dan;Karli, David
通讯作者：
Karli, David